GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » Net Income

Bioverativ (Bioverativ) Net Income : $356 Mil (TTM As of Dec. 2017)


View and export this data going back to 2017. Start your Free Trial

What is Bioverativ Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Bioverativ's Net Income for the three months ended in Dec. 2017 was $141 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2017 was $356 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Bioverativ's Earnings per Share (Diluted) for the three months ended in Dec. 2017 was $1.30.


Bioverativ Net Income Historical Data

The historical data trend for Bioverativ's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ Net Income Chart

Bioverativ Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Net Income
-344.60 -360.30 108.60 439.60 355.60

Bioverativ Quarterly Data
Dec13 Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 228.90 69.30 77.10 67.90 141.30

Bioverativ Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Bioverativ's Net Income for the fiscal year that ended in Dec. 2017 is calculated as

Net Income(A: Dec. 2017 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=451.9+-96.3+0+5.6843418860808E-14
=356

Bioverativ's Net Income for the quarter that ended in Dec. 2017 is calculated as

Net Income(Q: Dec. 2017 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=118.8+22.5+0+0
=141

Net Income for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $356 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioverativ  (NAS:BIVV) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Bioverativ's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2017 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Bioverativ Net Income Related Terms

Thank you for viewing the detailed overview of Bioverativ's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioverativ (Bioverativ) Business Description

Traded in Other Exchanges
N/A
Address
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox director, officer: Chief Executive Officer C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene officer: EVP, CFO and Treasurer 51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia director C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall officer: Chief Accounting Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio officer: EVP, Chief Global Therapeutics 225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r. officer: EVP, R & D C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona officer: EVP, HR & Corp Commun. Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick officer: EVP, Business Development BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

5 Companies Hit 52-Week Highs

By yifan900 yifan900 05-29-2018

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu 06-29-2017

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood 05-24-2017